|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2004-10-29
|
|
pubmed:abstractText |
Patients with relapsed malignant glioma have a poor prognosis. We developed a strategy of vaccination using autologous mature dendritic cells loaded with autologous tumour homogenate. In total, 12 patients with a median age of 36 years (range: 11-78) were treated. All had relapsing malignant glioma. After surgery, vaccines were given at weeks 1 and 3, and later every 4 weeks. A median of 5 (range: 2-7) vaccines was given. There were no serious adverse events except in one patient with gross residual tumour prior to vaccination, who repetitively developed vaccine-related peritumoral oedema. Minor toxicities were recorded in four out of 12 patients. In six patients with postoperative residual tumour, vaccination induced one stable disease during 8 weeks, and one partial response. Two of six patients with complete resection are in CCR for 3 years. Tumour vaccination for patients with relapsed malignant glioma is feasible and likely beneficial for patients with minimal residual tumour burden.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-10037230,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-10413158,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-10700726,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-11066055,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-11139371,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-11221866,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-11276199,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-11300335,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-11350875,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-11731436,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-11827989,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-11905751,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-11948109,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-12175345,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-12225360,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-12429623,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-12633662,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-1318961,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-14520441,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-14568975,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-14638850,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-15287461,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-2365829,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-6271933,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-7799011,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-8145033,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-8271027,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-8564842,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15477864-942051
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
pubmed-author:De VleeschouwerSS,
pubmed-author:DemaerelPP,
pubmed-author:FlamenPP,
pubmed-author:KühnHH,
pubmed-author:KaempgenEE,
pubmed-author:OpitzAA,
pubmed-author:PletsCC,
pubmed-author:RutkowskiSS,
pubmed-author:SörensenNN,
pubmed-author:Van CalenberghFF,
pubmed-author:Van GoolS WSW,
pubmed-author:Warmuth-MetzMM,
pubmed-author:WolffJ E AJE
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1656-62
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15477864-Adjuvants, Immunologic,
pubmed-meshheading:15477864-Adolescent,
pubmed-meshheading:15477864-Adult,
pubmed-meshheading:15477864-Aged,
pubmed-meshheading:15477864-Astrocytoma,
pubmed-meshheading:15477864-Brain Edema,
pubmed-meshheading:15477864-Cancer Vaccines,
pubmed-meshheading:15477864-Child,
pubmed-meshheading:15477864-Combined Modality Therapy,
pubmed-meshheading:15477864-Dendritic Cells,
pubmed-meshheading:15477864-Feasibility Studies,
pubmed-meshheading:15477864-Female,
pubmed-meshheading:15477864-Glioblastoma,
pubmed-meshheading:15477864-Humans,
pubmed-meshheading:15477864-Hypersensitivity, Delayed,
pubmed-meshheading:15477864-Male,
pubmed-meshheading:15477864-Middle Aged,
pubmed-meshheading:15477864-Neoplasm Recurrence, Local,
pubmed-meshheading:15477864-Vaccination
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study.
|
|
pubmed:affiliation |
Department of Pediatric Oncology, Children's Hospital, University of Wuerzburg, Josef-Schneider-Str. 2, D-97080 Wuerzburg, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
